Skip to main content
Fig. 3 | Molecular Cancer

Fig. 3

From: AMPK promotes antitumor immunity by downregulating PD-1 in regulatory T cells via the HMGCR/p38 signaling pathway

Fig. 3

Treatment with anti-PD-1 antibody reduces tumor growth in AMPKfl/flFoxp3-Cre mice. B16F10 melanoma tumor cells were injected subcutaneously into AMPK-WT and AMPKfl/flFoxp3-Cre mice. Anti-mouse PD-1 was administered i.p. at 200 μg/mouse at 8, 11, 14, and 17 days after the injection of cancer cells. Tumors were analyzed at day 20 post-tumor transplantation. The A volume and B weight of the tumors from WT and AMPKfl/flFoxp3-Cre mice treated with or without anti-PD-1 antibody. C Percentage of CD4+ and CD8+ T cells and CD4+Foxp3+ Tregs in the tumors of WT and AMPKfl/flFoxp3-Cre mice treated with or without anti-PD-1 antibody. D Flow cytometry analysis of the percentage of GZB- and IFN-γ-producing CD8 + T cells in lymphocytes isolated from tumor tissues. E Bar diagram representation of flow cytometric analysis of the percentage of Foxp3+IL-10+ T cells. F Flow cytometric analysis and MFI of ICOS and Nrp1 in the tumors of WT and AMPKfl/flFoxp3-Cre mice with or without anti-PD-1 treatment. The data are presented as the mean ± standard deviation (SD); n = 5 mice per group. *P < 0.05; **P < 0.01; ***P < 0.001

Back to article page